The article provides the current data on markers of myocardialischemia - ischemia modified albumin unbound free fatty acids and alludes also to cholin and glycogenphosphorylase B - markers on the border between myocardial ischemia and necrosis. Advantages and disadvantages of ischemia modified albumin are analysed with regards to the absence of sufficient number of evidence based data about this marker.
This is the main reason, which inhibits its clinical use. We have also very poor information about unbound free fatty acids and their laboratory analysis is very complicated.